SEC Form 4 · accession 0001140361-16-066308
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles N York II
Officer — Chief Financial Officer and VP
Period of report
May 17, 2016
Accepted (ET)
May 19, 2016 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $7.28 | May 17, 2016 | A | 55,000 | A | — | May 16, 2026 | Common Stock | 55,000 | 55,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.